…the enduring competitive advantages in a global economy lie increasingly in local things – knowledge, relationships, motivation – that distant rivals cannot match. When Michael Porter wrote this in 1998,…
As our current situation continues to evolve, it is critical that your out-licensing and/or financing business plans and presentations account for COVID-19. This should be communicated to prospective investors and…
Empty spaces. What are we living for? Abandoned places. I guess we know the score... Over the past few months, our industry has been thrust in a variety of different…
Will the current coronavirus situation affect biotech and pharma business development?Yes...and No. As with most things, the answer depends on your point of view, the market you happen to be in,…
Ophthalmology is changing. If we look back 5-10 years, topical formulations of novel or established drugs were the norm in ophthalmology product development. These days, we are seeing antisense, gene…
Our recent post entitled “What is confidential?” triggered a few questions and comments via email. Our latest post tackles these questions.
What is confidential? And what should you disclose before and after a CDA is signed?
Is Japan being ignored as a licensing partner in the biotech industry? Is China now getting all of the attention? Lacerta Bio explores this question.
Want to spend an entire decade surfing the web? Try finding and reading every article on “artificial intelligence.” A serious branch of computer science has rapidly turned into a buzzword…
Last week was another jam-packed week of meetings, this time at BIO-Europe Spring in Amsterdam. It is only our third appearance at this event, having participated in previous BIO…